These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17189418)

  • 1. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
    Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
    Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
    Rusk A; Cozzi E; Stebbins M; Vail D; Graham J; Valli V; Henkin J; Sharpee R; Khanna C
    Clin Cancer Res; 2006 Dec; 12(24):7456-64. PubMed ID: 17189419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
    Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
    J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma.
    Sahora AI; Rusk AW; Henkin J; McKeegan EM; Shi Y; Khanna C
    J Vet Intern Med; 2012; 26(5):1169-76. PubMed ID: 22816494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
    Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
    Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease.
    Punekar S; Zak S; Kalter VG; Dobransky L; Punekar I; Lawler JW; Gutierrez LS
    Pathobiology; 2008; 75(1):9-21. PubMed ID: 18334835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
    Baker LH; Rowinsky EK; Mendelson D; Humerickhouse RA; Knight RA; Qian J; Carr RA; Gordon GB; Demetri GD
    J Clin Oncol; 2008 Dec; 26(34):5583-8. PubMed ID: 18981463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: ABT-510, Abbott.
    Westphal JR
    Curr Opin Mol Ther; 2004 Aug; 6(4):451-7. PubMed ID: 15468604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
    Hoekstra R; de Vos FY; Eskens FA; Gietema JA; van der Gaast A; Groen HJ; Knight RA; Carr RA; Humerickhouse RA; Verweij J; de Vries EG
    J Clin Oncol; 2005 Aug; 23(22):5188-97. PubMed ID: 16051960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
    Ebbinghaus S; Hussain M; Tannir N; Gordon M; Desai AA; Knight RA; Humerickhouse RA; Qian J; Gordon GB; Figlin R
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6689-95. PubMed ID: 18006769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.
    Luo Y; Hradil VP; Frost DJ; Rosenberg SH; Gordon GB; Morgan SJ; Gagne GD; Cox BF; Tahir SK; Fox GB
    Anticancer Drugs; 2009 Jul; 20(6):483-92. PubMed ID: 19398903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
    Thamm DH; MacEwen EG; Phillips BS; Hershey AE; Burgess KM; Pettit GR; Vail DM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):251-5. PubMed ID: 11935218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1.
    Nunes SS; Outeiro-Bernstein MA; Juliano L; Vardiero F; Nader HB; Woods A; Legrand C; Morandi V
    J Cell Physiol; 2008 Mar; 214(3):828-37. PubMed ID: 17879962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment.
    Quesada AJ; Nelius T; Yap R; Zaichuk TA; Alfranca A; Filleur S; Volpert OV; Redondo JM
    Cell Death Differ; 2005 Jun; 12(6):649-58. PubMed ID: 15818399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma.
    Markovic SN; Suman VJ; Rao RA; Ingle JN; Kaur JS; Erickson LA; Pitot HC; Croghan GA; McWilliams RR; Merchan J; Kottschade LA; Nevala WK; Uhl CB; Allred J; Creagan ET
    Am J Clin Oncol; 2007 Jun; 30(3):303-9. PubMed ID: 17551310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombospondin-1 mimetic peptide ABT-898 affects neovascularization and survival of human endometriotic lesions in a mouse model.
    Nakamura DS; Edwards AK; Virani S; Thomas R; Tayade C
    Am J Pathol; 2012 Aug; 181(2):570-82. PubMed ID: 22727957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
    Anderson JC; Grammer JR; Wang W; Nabors LB; Henkin J; Stewart JE; Gladson CL
    Cancer Biol Ther; 2007 Mar; 6(3):454-62. PubMed ID: 17384534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration.
    Chan LY; Craik DJ; Daly NL
    Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26464514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.